Scienture Holdings, Inc. (SCNX) — SEC Filings
Scienture Holdings, Inc. (SCNX) — 50 SEC filings. Latest: 10-K (Mar 30, 2026). Includes 32 8-K, 6 10-Q, 3 10-K.
View Scienture Holdings, Inc. on SEC EDGAR
Overview
Scienture Holdings, Inc. (SCNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Scienture Holdings, Inc. (SCNX) is a clinical-stage biopharmaceutical company that became a wholly-owned subsidiary in July 2024, focusing on cardiovascular (CVS) and Central Nervous System (CNS) diseases. The company launched its first commercial product, SCN-102 (Arbli™) for hypertension, in Q1 20
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 6 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Scienture Holdings, Inc. is neutral.
Filing Type Overview
Scienture Holdings, Inc. (SCNX) has filed 3 10-K, 32 8-K, 6 10-Q, 2 S-1, 1 DEFA14A, 3 S-1/A, 1 DEF 14A, 1 10-K/A, 1 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SCNX's 46 recent filings, 6 were flagged as high-risk, 26 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Surendra Ajjarapu
- Michael L. R. Goldberg
- Jonathan L. R. Goldberg
- David L. R. Goldberg
Industry Context
Scienture Holdings operates in the highly competitive biopharmaceutical sector, focusing on the cardiovascular (CVS) and Central Nervous System (CNS) disease markets. These markets are characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. The industry is driven by innovation in drug discovery and a constant need for novel treatments for unmet medical needs, but also faces challenges from established players and patent expirations.
Top Tags
material-agreement (13) · 8-K (7) · corporate-action (6) · pharmaceuticals (6) · sec-filing (6) · company-name-change (5) · corporate-governance (5) · filing (4) · 10-Q (4) · delisting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Market Value of Non-Affiliate Common Stock | $10.2M | Indicates the public float as of the last business day of the most recently completed second fiscal quarter. |
| Common Shares Outstanding | 40.6M | Total shares outstanding as of March 27, 2026, relevant for dilution analysis. |
| Scienture LLC Operations Commencement | 2019 | Highlights the limited operating history of the core business. |
| SCN-102 (Arbli™) Launch | Q1 2025 | Marks the company's first commercial product, a critical step towards revenue. |
| Revenue for Q3 2025 | $590,050 | Increased 809% from $64,861 in Q3 2024 |
| Revenue for nine months ended Sep 30, 2025 | $600,308 | Increased 619% from $83,560 in the same period of 2024 |
| Net loss from continuing operations for Q3 2025 | $(3,607,361) | Widened from $(3,183,601) in Q3 2024 |
| Net loss from continuing operations for nine months ended Sep 30, 2025 | $(13,391,931) | Widened from $(11,441,764) in the same period of 2024 |
| Total operating expenses for nine months ended Sep 30, 2025 | $13,665,723 | Increased from $10,489,633 in the same period of 2024 |
| Cash as of September 30, 2025 | $355,692 | Slight increase from $308,096 at December 31, 2024 |
| Common shares outstanding on November 12, 2025 | 40,630,815 | Indicates significant dilution from 8,750,582 shares at Dec 31, 2024 |
| Gross proceeds from common stock issuance | $11,469,318 | Key source of cash for the nine months ended Sep 30, 2025 |
| Commission File Number | 001-39199 | SEC identifier for the company |
| I.R.S. Employer Identification No. | 46-3673928 | Tax identification number |
| Conformed Period of Report | 2025-06-30 | End date of the financial period covered by the 10-Q filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Scienture Holdings, Inc. (SCNX)?
Scienture Holdings, Inc. has 50 recent SEC filings from Jan 2024 to Mar 2026, including 32 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SCNX filings?
Across 50 filings, the sentiment breakdown is: 6 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Scienture Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Scienture Holdings, Inc. (SCNX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Scienture Holdings, Inc.?
Key financial highlights from Scienture Holdings, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SCNX?
The investment thesis for SCNX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Scienture Holdings, Inc.?
Key executives identified across Scienture Holdings, Inc.'s filings include Surendra Ajjarapu, Michael L. R. Goldberg, Jonathan L. R. Goldberg, David L. R. Goldberg.
What are the main risk factors for Scienture Holdings, Inc. stock?
Of SCNX's 46 assessed filings, 6 were flagged high-risk, 26 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Scienture Holdings, Inc.?
Forward guidance and predictions for Scienture Holdings, Inc. are extracted from SEC filings as they are enriched.